MA49444A - Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers hématologiques, utilisations et compositions pharmaceutiques associées - Google Patents

Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers hématologiques, utilisations et compositions pharmaceutiques associées

Info

Publication number
MA49444A
MA49444A MA049444A MA49444A MA49444A MA 49444 A MA49444 A MA 49444A MA 049444 A MA049444 A MA 049444A MA 49444 A MA49444 A MA 49444A MA 49444 A MA49444 A MA 49444A
Authority
MA
Morocco
Prior art keywords
mcl
inhibitor
combination
pharmaceutical compositions
hematological cancer
Prior art date
Application number
MA049444A
Other languages
English (en)
Inventor
Olivier Geneste
Ana-Leticia Maragno
Donia Moujalled
Giovanna Pomilio
Andrew Wei
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of MA49444A publication Critical patent/MA49444A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA049444A 2017-06-22 2018-06-21 Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers hématologiques, utilisations et compositions pharmaceutiques associées MA49444A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523389P 2017-06-22 2017-06-22
EP17189550 2017-09-06

Publications (1)

Publication Number Publication Date
MA49444A true MA49444A (fr) 2020-04-29

Family

ID=62631122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049444A MA49444A (fr) 2017-06-22 2018-06-21 Combinaison d'un inhibiteur de mcl-1 et d'un standard de traitement de soin pour cancers hématologiques, utilisations et compositions pharmaceutiques associées

Country Status (28)

Country Link
US (1) US11466023B2 (fr)
EP (1) EP3641775B1 (fr)
JP (1) JP7186731B2 (fr)
KR (1) KR20200018681A (fr)
CN (2) CN117959451A (fr)
AR (1) AR112202A1 (fr)
AU (1) AU2018288520B2 (fr)
BR (1) BR112019026959A2 (fr)
CA (1) CA3068096C (fr)
CL (1) CL2019003763A1 (fr)
CO (1) CO2019014479A2 (fr)
CU (1) CU20190105A7 (fr)
EA (1) EA202090082A1 (fr)
ES (1) ES2971466T3 (fr)
GE (2) GEP20227357B (fr)
IL (1) IL271475B2 (fr)
JO (1) JOP20190287B1 (fr)
MA (1) MA49444A (fr)
MX (1) MX393811B (fr)
MY (1) MY199286A (fr)
NI (1) NI201900128A (fr)
PH (1) PH12019502789A1 (fr)
SG (1) SG11201911891WA (fr)
TW (1) TWI753178B (fr)
UA (1) UA126920C2 (fr)
UY (1) UY37777A (fr)
WO (1) WO2018234433A1 (fr)
ZA (1) ZA201908446B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3222752A1 (fr) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des conjugues anti-corps-medicament
EP4351564A1 (fr) 2021-06-11 2024-04-17 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des agents anticancéreux

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2504611A1 (fr) 2002-11-06 2004-05-27 Wyeth Therapie combinee de traitement de la leucemie aigue et du syndrome myelodysplasique
US9079970B2 (en) 2008-12-09 2015-07-14 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of MCL-1
EP2558866B1 (fr) * 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentialisation de l'activité anticancéreuse par polythérapie avec des inhibiteurs de la voie ber
CA2712747A1 (fr) * 2010-08-11 2012-02-11 Universite De Montreal Traitement d'association contre le cancer
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA036001B1 (ru) * 2014-06-13 2020-09-11 Калитера Байосайенсиз, Инк. Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких
FR3037958B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037959B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives bicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037956B1 (fr) 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018236904A1 (fr) * 2017-06-19 2018-12-27 Surface Oncology, Inc. Combinaison d'anticorps anti-cd47 et d'agents induisant la mort cellulaire, et leurs utilisations

Also Published As

Publication number Publication date
CN111032050A (zh) 2020-04-17
NI201900128A (es) 2020-03-30
IL271475A (en) 2020-01-30
SG11201911891WA (en) 2020-01-30
US11466023B2 (en) 2022-10-11
EP3641775A1 (fr) 2020-04-29
CA3068096A1 (fr) 2018-12-27
MX393811B (es) 2025-03-24
ZA201908446B (en) 2023-10-25
UY37777A (es) 2019-01-31
EP3641775B1 (fr) 2023-12-06
CL2019003763A1 (es) 2020-06-19
AR112202A1 (es) 2019-10-02
PH12019502789A1 (en) 2020-09-14
GEAP202115242A (en) 2021-11-10
RU2020101626A (ru) 2021-07-22
GEP20227357B (en) 2022-02-25
IL271475B2 (en) 2023-09-01
UA126920C2 (uk) 2023-02-22
TW201904579A (zh) 2019-02-01
TWI753178B (zh) 2022-01-21
CA3068096C (fr) 2022-10-04
EA202090082A1 (ru) 2020-05-22
JOP20190287B1 (ar) 2024-04-16
US20200392151A1 (en) 2020-12-17
KR20200018681A (ko) 2020-02-19
CN111032050B (zh) 2024-01-19
MY199286A (en) 2023-10-24
AU2018288520A1 (en) 2020-01-16
RU2020101626A3 (fr) 2021-10-05
CN117959451A (zh) 2024-05-03
WO2018234433A1 (fr) 2018-12-27
IL271475B1 (en) 2023-05-01
JP2020524681A (ja) 2020-08-20
JP7186731B2 (ja) 2022-12-09
AU2018288520B2 (en) 2024-05-30
ES2971466T3 (es) 2024-06-05
CU20190105A7 (es) 2020-10-20
CO2019014479A2 (es) 2020-02-28
JOP20190287A1 (ar) 2019-12-16
BR112019026959A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
EP3829595A4 (fr) Complexes de ciblage musculaire et leurs utilisations pour le traitement de dystrophinopathies
MA55206A (fr) Polyribonucléotides circulaires et compositions pharmaceutiques associées
HRP20260108T1 (hr) Kombinirana terapija koja uključuje inhibitor kras-g12c i jedan ili više dodatnih farmaceutski aktivnih sastojaka za liječenje raka
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
EP3548000A4 (fr) Compositions pharmaceutiques d'atropine
EP3630072A4 (fr) Procédés et compositions pour le traitement d'une somnolence excessive
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3723752A4 (fr) Nouvelles formes solides de cannabidiol et utilisations associées
EP2868667A4 (fr) Agent thérapeutique à base d'anticorps anti-bmp9 en tant que principe actif, pour le traitement de l'anémie, notamment une anémie rénale et une anémie liée à un cancer
EP3407976A4 (fr) Compositions et utilisations d'agents alpha-adrénergiques
EP3500255A4 (fr) Compositions pharmaceutiques ophtalmiques et utilisations associées
EP3810601A4 (fr) Composés pyrimidine et compositions pharmaceutiques pour la prévention ou le traitement de cancers les comprenant
EP3573614C0 (fr) Compositions pharmaceutiques pour thérapie combinée
EP3946316A4 (fr) Compositions pharmaceutiques de cannabidiol
EP3906019C0 (fr) Compositions pharmaceutiques de furosémide
EP3658554A4 (fr) Composés dihydropyrimidine et utilisations de ceux-ci en médecine
EP3397262A4 (fr) Combinaison d'inhibiteur de hdac et d'anticorps anti-pd-l1 pour le traitement de cancer des ovaires
EP3651801A4 (fr) Compositions et méthodes pour le traitement d'infections fongiques
EP3817774A4 (fr) Compositions et méthodes pour l'administration locale d'agents pharmaceutiques pour traiter le cancer
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
IT201700025666A1 (it) Composizione per l’uso nel trattamento dell’ipercolesterolemia e nella prevenzione di patologie cardiovascolari.
EP4041274A4 (fr) Utilisations de ws-635 en médecine
EP3570835A4 (fr) Méthodes et compositions pharmaceutiques pour la prévention ou le traitement d'affections dermiques immuno-inflammatoires
EP3773613A4 (fr) Compositions pharmaceutiques contenant des polyrotaxanes